Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics has announced the addition of Dr. Ronald Perrone to its Clinical Advisory Board, bringing his extensive experience in nephrology and clinical research on polycystic kidney disease to support the company’s advanced clinical programs, including the XRX-OXY-201 registration trial for ADPKD. Dr. Perrone’s involvement in pivotal clinical trials and regulatory discussions will bolster XORTX’s commitment to developing therapies aimed at improving patient outcomes in kidney diseases. The company continues to focus on medications that target purine metabolism disturbances and are in various stages of clinical development.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
